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Abstract
Cancer cells generally exhibit increased glycolysis for ATP
generation (the Warburg effect) due in part to mitochondrial
respiration injury and hypoxia, which are frequently associ-
ated with resistance to therapeutic agents. Here, we report
that inhibition of glycolysis severely depletes ATP in cancer
cells, especially in clones of cancer cells with mitochondrial
respiration defects, and leads to rapid dephosphorylation of
the glycolysis-apoptosis integrating molecule BAD at Ser
112,
relocalization of BAX to mitochondria, and massive cell
death. Importantly, inhibition of glycolysis effectively kills
colon cancer cells and lymphoma cells in a hypoxic environ-
ment in which the cancer cells exhibit high glycolytic activ-
ity and decreased sensitivity to common anticancer agents.
Depletion of ATP by glycolytic inhibition also potently in-
duced apoptosis in multidrug-resistant cells, suggesting that
deprivation of cellular energy supply may be an effective
way to overcome multidrug resistance. Our study shows a
promising therapeutic strategy to effectively kill cancer cells
and overcome drug resistance. Because the Warburg effect
and hypoxia are frequently seen in human cancers, these
findings may have broad clinical implications. (Cancer Res
2005; 65(2): 613-21)
Introduction
Over 70 years ago, Warburg (1) observed that cancer cells
frequently exhibit increased glycolysis and depend largely on this
metabolicpathwayforgenerationofATPtomeettheirenergyneeds.
Heattributedthismetabolicalterationtomitochondrial‘‘respiration
injury’’ and considered this as the most fundamental metabolic
alteration in malignanttransformation or ‘‘the origin of cancer cells’’
(2). During the past several decades, the Warburg effect has been
consistently observed in a wide spectrum of human cancers,
although the underlying biochemical and molecular mechanisms
are extremely complex and remain to be defined. Among the
possiblemechanisms,mitochondrialmalfunctionandhypoxiainthe
tumor microenvironment are considered two major factors
contributing to the Warburg effect. However, whether the increase
of glycolytic activity in cancer cells is mainly due to inherent
metabolic alterations or due to anaerobic environment in the tumor
tissues remains controversial (3).
Under physiologic conditions, generation of ATP through
oxidative phosphorylation in the mitochondria is an efficient and
preferred metabolic process, which produces far more ATP
molecules from a given amount of glucose compared with
glycolysis. However, when the ability of cells to generate ATP
through mitochondrial oxidative phosphorylation is compro-
mised, cells are able to adapt alternative metabolic pathways,
such as increasing glycolytic activity, to maintain their energy
supply. Mitochondrial respiratory function can be negatively
affected by multiple factors, including mutations in mitochon-
drial DNA (mtDNA), malfunction of the electron transport chain,
aberrant expression of enzymes involved in energy metabolism,
and insufficient oxygen available in the cellular microenviron-
ment. It is known that mtDNA contains a displacement loop,
and the coding gene sequence for 13 important protein
components of the mitochondrial respiratory complexes without
introns. Mutations in mtDNA are likely to cause alterations of
the encoded protein and compromise the respiratory chain
function. Thus, the frequent mtDNA mutations observed in a
variety of human cancers are thought to contribute to
respiratory malfunction in cancer cells (4–6). The constant
generation of reactive oxygen species within the mitochondria
and the increased free radical stress in cancer cells may cause
further damage to both mtDNA and the electron transport
chain, thus amplifying respiratory malfunctions and dependency
on glycolysis (7).
Hypoxia is another important factor that contributes to the
Warburg effect. The fast growth of cancer cells and rapid expansion
of the tumor mass usually outpace new vascular generation,
resulting in an insufficient blood supply to certain area of the
tumor tissues. Such a hypoxic environment within the tumor mass
limits the availability of oxygen for use in mitochondrial respiration
and synthesis of ATP and forces the cancer cells to up-regulate the
glycolytic pathway as the main route of energy production (8).
The ability of oxygen to regulate glucose metabolism is know as the
Pasteur effect and is mediated through several pathways involving
various kinases (9, 10). In this case, the increased glycolytic activity
in cancer cells is not necessarily due to intrinsic mitochondrial
defects but is induced by the tumor microenvironment through a
series of metabolic adaptation processes, including preferentially
increased expression of enzymes required for glycolysis (11).
Although the underlying mechanisms responsible for the
Warburg effect are rather complex and can be attributed to a
variety of factors, such as mitochondrial defects and hypoxia, the
metabolic consequences seem similar. The compromised ability of
cancer cells to generate ATP through oxidative phosphorylation
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Research Articleforces the cells to increase glycolysis to maintain their energy
supply and thus renders cancer cells highly dependent on this
metabolic pathway for survival. As such, it is conceivable that the
metabolic alterations in malignant cells may be exploited to serve
as a biochemical basis to develop therapeutic strategies to target
this metabolic abnormality. One possibility is to inhibit glycolysis
and preferentially kill the cancer cells that are dependent on
glycolytic pathway for ATP generation.
Several agents, including 2-deoxyglucose and arsenate com-
pounds, have long been known to abolish ATP generation
through the glycolytic pathway. For instance, 2-deoxyglucose is
an analogue of glucose and is able to bind and suppress
hexokinase II, an enzyme that catalyzes the initial metabolic step
in the conversion of glucose to glucose-6-phosphate during
glycolysis (12). Inhibition of this rate-limiting step by 2-
deoxyglucose causes a depletion of cellular ATP, leading to
blockage of cell cycle progression and cell death in vitro, and
exhibits antitumor activity in vivo (13, 14). However, the
effectiveness of 2-deoxyglucose is significantly affected by the
presence of its natural counterpart glucose and seems to only
partially reduce the availability of glucose for glycolysis (12). In
contrast, the pentavalent arsenic compounds do not directly
inhibit glycolysis but abolish net ATP generation by causing
arsenolysis in the glyceraldehyde-3-phosphate dehydrogenase
reaction, preventing the generation of 1,3-bisphosphoglycerate.
However, the pentavalent arsenic compounds seem to have
limited specificity due to other toxic effects. More recent studies
showed that 3-bromopyruvate (3-BrPA) is a potent inhibitor of
hexokinase II and effectively inhibits glycolysis (12, 15). This
compound is effective in killing liver cancer cells in the rabbit
VX2 tumor implantation animal tumor model when given by
local infusion (16).
In the present study, we used defined experimental systems to
examine the potential therapeutic implications of the Warburg
effect by testing the sensitivity of cancer cells to glycolytic
inhibition under hypoxic and normoxic conditions and of cancer
cells with genetic mitochondrial defects. We showed that cancer
cells with such respiratory abnormalities were less sensitive to
chemotherapeutic agents commonly used in the clinical
treatment of cancer but could be effectively killed by inhibition
of glycolysis using 3-BrPA. We also observed that inhibition of
glycolysis caused a rapid dephosphorylation of BAD protein at
Ser
112, leading to BAX localization to mitochondria and massive
cell death. Importantly, cells that express a multidrug-resistant
(MDR) phenotype still remain sensitive to inhibition of glycolysis.
Because alterations in energy metabolism and increased
dependency on glycolysis are commonly seen in cancer cells,
our findings suggest potential broad therapeutic implications of
using glycolytic inhibitors for cancer treatment.
Materials and Methods
Chemicals and Reagents. 3-BrPA was purchased from Sigma (St. Louis,
MO). The compound was dissolved into water and neutralized with NaOH
immediately before use in cell culture. [
3H]2-deoxyglucose and [
3H]2-leucine
were purchased from Amersham (Piscataway, NJ). Mouse monoclonal anti-
pBAD(Ser
112), rabbit anti-caspase-3, rabbit polyclonal anti-pAkt(Ser
473), and
rabbit polyclonal anti-BAD antibodies were purchased from Cell Signaling
Technology, Inc. (Beverly, MA). Rabbit polyclonal anti–cytochrome c was
from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-
BAX was purchased from BD Biosciences (San Diego, CA).
Cells and Cell Culture. Human leukemia cell line HL-60 and human
lymphoma cell line Raji were cultured in RPMI 1640 supplemented with
10% fetal bovine serum at 37jC in a humidified atmosphere with 5% CO2.
The mitochondrial defective clones (U
 cells) HL-60/C6F and Raji/C8 were
derived as described previously (17, 18) and maintained in RPMI 1640
supplemented with 10% fetal bovine serum, 1 mmol/L sodium pyruvate,
50 mmol/L uridine, and additional 2.7% glucose. Human colon cancer
HCT116 cells were maintained in McCoy’s 5A medium supplemented with
10% fetal bovine serum. A hypoxic culture condition was created by
incubating cells in a sealed modular incubator chamber (Billups-
Rothenberg, Del Mar, CA) flushed with 5% CO2 and 95% N2. Because
the culture flasks contained ambient oxygen at the beginning of the
experiments, the final oxygen content in the hypoxia chamber wasf0.5%
to 1.0% after achieving air equilibrium.
Cytotoxicity Assays. Cell growth inhibition was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assay using
MTT reagent in 96-well plates. After 72 hours of drug incubation, 50 AL
MTT reagent was added to each well and incubated for an additional
4 hours. The plates were then centrifuged (1,500  g, 5 minutes) and the
supernatant was removed. The cell pellets were dissolved in 200 ALD M S O .
Absorbance was determined using a MultiSkan plate reader (LabSystems,
Helsinki, Finland) at a wavelength of 570 nm. Apoptotic or necrotic cell
death was determined by flow cytometric analysis of cells double stained
with Annexin V-FITC and propidium iodide (PI) using an assay kit from
BD PharMingen (San Diego, CA). Briefly, after drug incubation, cells were
collected, washed with cold PBS, and suspended in Annexin V binding
buffer. The cells were stained with Annexin V-FITC for 15 minutes at room
temperature in the dark, washed, and stained with PI. The samples were
analyzed with a FACSCalibur flow cytometer with CellQuest Pro software.
Measurement of Cellular ATP Pool. Cells were incubated with various
concentrations of 3-BrPA for indicated time intervals. Intracellular
nucleotides were extracted from the cells with 0.4 N perchloric acid,
neutralized with concentrated KOH, and quantitated as described
previously (19). Briefly, nucleotides in the cell extracts were analyzed by
HPLC using an anion exchange Partisil-10 SAX column with an elution
flow rate of 1.5 mL/min over a 50-minute buffer gradient [curve 5, buffer A:
0.005 mol/L NH4H2PO4 (pH 2.8); buffer B: 0.5 mol/L NH4H2PO4 + 0.25 mol/L
KCl (pH 2.8)]. The eluting flow was continuously monitored by UV
absorption at 262 nm, and the peaks of nucleoside triphosphates were
quantitated by electronic integration with reference to external standards.
The intracellular ATP contents were calculated and normalized by equal
cell number and expressed as percentage of the control cells.
Determination of Glycolytic Activity. The cellular glycolytic activity
under various experimental conditions was evaluated by measuring the
glycolytic index, which was calculated by the formula: glycolytic index =
(L  G)/O, where L is the cellular lactate generation rate, G is glucose
uptake rate, and O is the oxygen consumption rate. To determine the
cellular lactate production, cells in exponential growth phase were
washed and incubated with fresh medium for the indicated times.
Aliquots of the culture medium were removed for the analysis of lactate
content using an Accutrend lactate analyzer with a linear range of
standard lactate concentrations according to the procedures recommen-
ded by the manufacturer (Roche, Mannheim, Germany). Cellular glucose
uptake was measured by incubating cells in glucose-free RPMI 1640
with 0.2 Ci/mL [
3H]2-deoxyglucose (specific activity, 40 Ci/mmol) for
60 minutes. After the cells were washed with ice-cold PBS, the radio-
activity in the cell pellets was quantified by liquid scintillation counting.
To determine cellular oxygen consumption, cells were resuspended in
1 mL fresh warm medium pre-equilibrated with 21% oxygen and placed
in the sealed respiration chamber equipped with a thermostat control,
a microstirring device, and a Clark-type oxygen electrode disc (Oxytherm,
Hansatech Instrument, Cambridge, United Kingdom). The oxygen content
in the cell suspension medium was constantly monitored and oxygen
consumption rate was determined as described previously (17).
Western Blot Analysis. Proteins in whole cell lysates, mitochondrial
fractions, or cytosolic fractions were resolved by electrophoresis on SDS-
PAGE and transferred to nitrocellulose membranes. The membranes were
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112)
(1:1,000), anti-pAkt/Ser
473 (1:1,000), anti-BAX (1:1,000), anti–cytochrome
c (1:1,000), or anti-caspase-3 (1:1,000) overnight. The bound primary
antibodies were detected using appropriate horseradish peroxidase–
conjugated secondary antibodies followed by detection with a SuperSignal
enhanced chemiluminescence kit (Pierce, Rockford, IL). For sequential
blotting, the membranes were stripped with a stripping buffer (Pierce)
followed by reblotting with proper antibodies. To prepare mitochondrial
and cytosolic fractions, cells were harvested, washed once with ice-cold
PBS, and resuspended in 3 volumes of isolation buffer [20 mmol/L HEPES
(pH 7.4), 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, 1 mmol/L
DTT, 250 mmol/L sucrose, and a cocktail of protease inhibitors]. After
keeping in an ice bath for 10 minutes, the cell suspension was
homogenized with 15 strokes in a 2 mL glass homogenizer. The samples
were centrifuged twice at 1,500  g at 4jC for 5 minutes to remove nuclei,
unbroken cells, and cell debris. The supernatants were centrifuged again at
15,000  g for 15 minutes to separate the mitochondrial fraction (pellets)
and the cytosolic fraction (supernatants). The mitochondria pellet was
washed once with the isolation buffer before use.
Results
Alterations of Drug Sensitivity in Cancer Cells with
Respiratory Deficiency or under Hypoxic Conditions. We first
established in vitro experimental systems to examine the effects of
mitochondrial defects and hypoxia, two major underlying factors of
the Warburg effect, on cellular sensitivity to various anticancer
agents. Clones of cells with mitochondrial respiratory defects were
derived from human leukemia cells (HL-60) and human lymphoma
cells (Raji) by preferentially damaging the mtDNA. The procedures
to derive respiration-defect clones (U
 cells) and their biochemical
and molecular characterization were described previously (17, 18).
One such U
 clone, C6F derived from HL-60 cells, contained
multiple mutations in their mtDNA and were completely defective
in mitochondrial respiration (17). Transmission electron micros-
copy analysis revealed that mitochondria in C6F cells are abnor-
mally swollen, with pale matrix and disorganized cristae (Fig. 1A).
Biochemical analysis showed that C6F cells consumed little oxygen
(Fig. 1B), indicating that these cells were severely deficient in
mitochondrial respiration. Compared with the parental HL-60 cells,
C6Fcells were more active in glucose uptake (P = 0.008; Fig. 1C) and
produced significantly more lactate (end product of glycolytic
metabolism), which was released and accumulated in the culture
medium (P = 0.002; Fig. 1D). The lack of oxygen consumption,
increase in glucose uptake, and lactate accumulation in C6F cells
indicate that the glycolytic pathway is highly active in these cells.
Using these three major biochemical variables, we calculated that
the glycolytic indexes for the HL-60 parental cells and C6Fcells were
Figure 1. Characterization of cancer cells with
mitochondrial defects and alterations in drug sensitivity. A,
comparison of mitochondrial morphology in HL-60 and the
respiratory-deficient C6F clone by transmission electron
microscopy analysis. Note the swollen mitochondria with
significant pale matrix and disorganized cristae in C6F
cells. B, oxygen consumption in HL-60 and C6F cells. C,
comparison of glucose uptake in HL-60 and C6F cells.
Cells (f2.5  10
6) were incubated in 5 mL RPMI 1640
(glucose-free) with 0.2 Ci/mL [
3H]2-deoxyglucose for 1
hour, and the uptake of radioactivity was determined as
described in MATERIALS AND METHODS. Columns,
mean of three independent experiments; bars, SD. D,
lactate production in HL-60 and C6F cells. Cells in
exponential growth phase were resuspended in RPMI
1640 at the density of 5  10
5/mL and incubated for
24 hours, and the lactate concentration in the culture
medium was measured as described in MATERIALS AND
METHODS. Columns, mean of three independent
experiments; bars, SD. E, comparison of drug sensitivity
in HL-60 and C6F cells. Cells were incubated with the
indicated concentrations of doxorubicin (doxo), ara-C,
taxol, and vincristine (VCR) for 24 hours, and cell death
was analyzed by flow cytometry for positive Annexin V
staining.
Overcome Drug Resistance by Inhibition of Glycolysis
www.aacrjournals.org 615 Cancer Res 2005; 65: (2). January 15, 20052.4 and 45.6, respectively. Similar biochemical alterations indicative
of highly increased glycolysis were also observed in the U
 cell
clones derived from the Raji cells.
Because mitochondria playimportant roles in energy metabolism
as well as in regulation of apoptosis, we then examined the effect of
mitochondrial respiratory defects on the cellular response to
anticancer agents by comparing the drug sensitivity of HL-60 and
C6F cells. As shown in Fig. 1E, the respiration-deficient C6F cells
were substantially less sensitive than the parental cells to several
anticancer agents commonly used in the clinic. These therapeutic
agents include 1-h-D-arabinofuranosylcytosine (ara-C), doxorubicin
(Adriamycin), taxol,andvincristine.Therewasaconsistentdecrease
of drug sensitivity in C6F cells for each agent tested, with the most
reduced sensitivity observed with taxol and vincristine. Similarly,
reduced drug sensitivity was also observed in the U
 cells derived
from Raji cells (data not shown). Thus, mitochondrial respiration
deficiency not only caused increased glycolysis but also blunted the
cellular responses to anticancer agents.
Hypoxia is another major factor that causes cancer cells to adapt
glycolysis to generate ATP. We next tested if this metabolic
adaptation might, as in the cells with mitochondrial defects, also
alter the cellular sensitivity to anticancer agents. The lymphoma cell
line Raji and a solid tumor cell line HCT116 (human colon cancer)
were used to test this possibility. As illustrated in Fig. 2, cells
incubated under hypoxic conditions produced a significantly
greater amount of lactate than under normoxia during the same
incubation period (P = 0.0015; Fig. 2A), confirming an increase in
glycolytic activity when cells were deprived of oxygen. This
metabolic adaptation was accompanied by a reduced sensitivity
to doxorubicin and ara-C. This decrease in drug sensitivity was
consistently observed in both HCT116 cells (Fig. 2B) and Raji cells
(Fig. 2C). These data, together with the observations in the U
 cells,
suggest that cancer cells with increased glycolysis, due either to
mitochondrial genetic defects or to environmental hypoxia, become
less sensitive to common anticanceragents. This reduced sensitivity
was not due to a general slowing down of the cell death process,
because these cells exhibited a greater sensitivity to glycolytic
inhibition under similar incubation conditions (see below).
Inhibition of Glycolysis Effectively Kills Cancer Cells with
Respiratory Defects. The above observations prompted us to
explore new strategies to effectively kill cancer cells and
overcome drug resistance associated with hypoxia or mitochon-
drial defects. One logical approach is to inhibit glycolysis and
thus block the major metabolic pathway by which the
respiration-deficient cancer cells generate their ATP. 3-BrPA,
a known inhibitor of hexokinase II with a potent inhibitory
effect on glycolysis (12, 15, 16), was used in our study to test this
possibility. As shown in Fig. 3A and B, incubation of HL-60 cells
with 3-BrPA caused a concentration- and time-dependent
depletion of the cellular ATP pool, confirming its ability to
block energy metabolism in this cell line. 3-BrPA also caused
massive cell death in a concentration- and time-dependent
manner as evidenced by positive Annexin V staining and loss of
membrane integrity (positive PI staining) revealed by flow
cytometry analysis (Fig. 3C and D). The ability of this compound
to induce cell death was correlated with its ability to deplete
cellular ATP. It should be noted that a nearly complete depletion
of ATP occurred 3 to 6 hours after cells were incubated with
300 Amol/L 3-BrPA (Fig. 3B), whereas significant cell death was
not observed until 12 to 24 hours (Fig. 3D), indicating that ATP
depletion occurred before the onset of cell death.
Because the proapoptotic Bcl-2 family member BAD has been
shown to play an important role in integrating glycolysis and
apoptosis (20), we tested the possibility that inhibition of
glycolysis by 3-BrPA might affect the proapoptotic function of
BAD. As shown in Fig. 4A, incubation of HL-60 cells with this
compound caused a concentration- and time-dependent dephos-
phorylation of BAD at Ser
112, with a complete dephosphorylation
Figure 2. Hypoxia caused an increase in glycolytic activity and a decrease in
drug sensitivity. A, lactate generation in HCT116 cells under normoxic and
hypoxic conditions. HCT116 were seeded in culture flasks at a density of
1  10
6 cells per flask (T-25) and incubated for 24 hours under normoxic
conditions. The culture medium was then replaced with fresh medium, and the
samples were incubated for 36 hours under either normoxic or hypoxic
conditions. Lactate concentration in the culture medium was measured as
described in MATERIALS AND METHODS, and the rate of lactate production
was calculated. Columns, mean of three independent experiments; bars, SD. B,
comparison of drug sensitivity under normoxic and hypoxic conditions in HCT116
cells. Cells were treated with ara-C (1 Amol/L) or doxorubicin (1 Amol/L) for 36
hours under normoxic or hypoxic conditions, and cell death was measured by
flow cytometric analysis as described in MATERIALS AND METHODS. C,
comparison of drug sensitivity under normoxic and hypoxic conditions in Raji
cells. Cells were treated with ara-C (0.3 Amol/L) or doxorubicin (0.3 Amol/L) for
24 hours under normoxic or hypoxic conditions. Cell death was measured by flow
cytometric analysis.
Cancer Research
Cancer Res 2005; 65: (2). January 15, 2005 616 www.aacrjournals.org8 hours after drug incubation. Interestingly, 3-BrPA did not cause
a decrease in total BAD protein. Instead, there was a detectable
increase of total BAD after the drug incubation (Fig. 4A). The
inhibitory effect of 3-BrPA on BAD phosphorylation was also
observed under hypoxic conditions and seemed to be specific for
BAD because the phosphorylation status of another protein Akt
was not decreased under identical conditions (Fig. 4B). It is
known that the BH3 domain-only member BAD requires the
multidomain proapoptotic members such as BAX to trigger the
mitochondrial apoptotic pathway and that Bcl-2 and Bcl-XL can
sequester these proapoptotic factors by forming complexes to
prevent apoptosis (21). We speculated that the increased amount
of dephosphorylated BAD in cells treated with 3-BrPA might
displace BAX from this sequestering complex, allowing BAX to
localize to the mitochondria and cause a change in membrane
permeability and the release of cytochrome c. Western blot
analysis of the mitochondrial and cytosolic protein fractions
showed that, when BAD was dephosphorylated, there was a
concurrent increase of BAX protein in the mitochondrial
fraction, accompanied by a simultaneous decrease of cytosolic
BAX (Fig. 4C), suggesting a translocation of BAX to the
mitochondria. The release of cytochrome c from the mitochon-
dria to the cytosol and cleavage of caspase-3 were also detected
at these time points (Fig. 3C and D). These data suggest that
inhibition of glycolysis significantly affected the phosphorylation
status of BAD, leading to BAX translocation to the mitochondria.
Because respiration-deficient cancer cells are highly dependent
on glycolysis, we reasoned that inhibition of glycolysis by 3-BrPA
might have a profound effect on cells with respiratory defects. Two
clones of the U
 cells, C6F and C8 derived from parental HL-60 and
Raji cells, respectively, were used to test this possibility. As shown
Figure 3. Induction of ATP depletion and cell death in HL-60 cells by 3-BrPA. A,
HL-60 cells were treated with the indicated concentrations of 3-BrPA for
12 hours. Intracellular ATP was measured by HPLC analysis as described in
MATERIALS AND METHODS and expressed as percentage of the control. ATP
content of the control cells was 2.6 F 0.1 nmol per 10
6 cells. Columns, mean
of three independent experiments; bars, SD. B, time-dependent depletion of
ATP in HL-60 cells treated with 3-BrPA. Cells were incubated with the indicated
concentrations of 3-BrPA for various times, and cellular ATP was determined as
described above. Points, mean of three independent experiments; bars, SD. C,
concentration-dependent cell death in HL-60 cells treated with 3-BrPA. Cell
death was measured by flow cytometric analysis of cells double stained with
Annexin V and PI. D, time-dependent apoptosis in HL-60 cells treated with
3-BrPA. Cells were incubated with the indicated concentrations of 3-BrPA for
various times and analyzed by flow cytometry after double staining with
Annexin V and PI. Points, mean of three independent experiments; bars, SD.
Figure 4. Dephosphorylation of BAD and alterations of mitochondrial and
cytosolic BAX and cytochrome c in HL-60 cells treated with 3-BrPA. A, HL-60
cells were incubated with 100-300 Amol/L 3-BrPA for the indicated times. Equal
amounts of total cellular proteins from each sample were resolved by SDS-PAGE
and blotted for total BAD protein, pBAD(Ser
112), and h-actin. B, effect of 3-BrPA
on the phosphorylation status of BAD and Akt. HL-60 and C6F cells were treated
with 100 Amol/L 3-BrPA under hypoxic or normoxic conditions for 8 hours as
indicated. Cell lysates were subjected to Western blot analysis using
anti-pBAD(Ser
112), anti-pAkt(Ser
473), and anti-h-actin antibodies. C,
translocation of BAX to mitochondria and release of cytochrome c to cytosol
in cells treated with 3-BrPA. Mitochondrial and cytosolic fractions were isolated
from HL-60 cells treated with 100 Amol/L 3-BrPA for the indicated times and
blotted for BAX and cytochrome c (Cyt-c) as described in MATERIALS AND
METHODS. Mitochondrial HSP60 protein and cytosolic h-actin were also blotted
as protein loading controls. D, cytosolic fractions were blotted for caspase-3
using an antibody that detects both procaspase-3 and cleaved fragments.
Overcome Drug Resistance by Inhibition of Glycolysis
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caused a significantly greater depletion of ATP in both U
 clones
compared with their respective parental cell lines. A higher
concentration (300 Amol/L) led to complete depletion of ATP in
both U
 cells and parental cells. The U
 cells were also more
sensitive to 3-BrPA-mediated BAD dephosphorylation, which
occurred 1 to 3 hours after drug incubation (Fig. 5C and D).
Importantly, analysis of cytotoxicity revealed that both U
 clones
were substantially more sensitive to 3-BrPA than their parental
cells (Fig. 5E and G). For instance, incubation of C6F or C8 cells
with 100 Amol/L 3-BrPA for 24 hours caused cell death in most all
of the U
 cells, whereas a portion of the parental cells still
remained intact after the same drug incubation (Fig. 5E). This is in
direct contrast with the results shown in Fig. 1, in which the
respiration-defect cells were less sensitive to common anticancer
agents, such as doxorubicin, ara-C, and taxol.
Inhibition of Glycolysis Effectively Kills Cancer Cells under
Hypoxic Conditions. The findings shown in Fig. 5 prompted us to
further test the possibility to use 3-BrPA to effectively kill cancer
cells under hypoxic conditions, which also rendered the cells
dependent on glycolysis and less sensitive to common anticancer
agents(Fig.2). Incubationoflymphomacells(Raji)andcoloncancer
cells (HCT116) with 3-BrPA under hypoxic conditions caused a
significant inhibition of glycolysis as shown by the decrease of
lactate production (Fig. 6A and B). Both cell lines were more
sensitive to 3-BrPA under hypoxic conditions than under normoxic
conditions as shown by a substantial increase in percentage of cells
with Annexin V/PI–positive staining (Fig. 6C and D).
MDR Cells Remain Sensitive to Glycolytic Inhibition.Because
inhibition of glycolysis by 3-BrPA causes a severe depletion of
cellular ATP, we speculated that this compound might be able to
effectively kill MDR cells, which use ATP-dependent molecular
pumpstoexportvariousanticancerdrugsoutofthecells.Totestthis
possibility, we used a previously characterized MDR cell line HL-60/
AR derived from HL-60 cells (22) and examined its sensitivity to
3-BrPA in comparison with several common anticancer agents.
As expected, the MDR cells HL-60/AR are highly resistant to
both doxorubicin and vincristine, with the IC50 values f1,000
times greater than that of the parental cells (Fig. 7A and B). The
HL-60/AR cells also exhibited reduced sensitivity to ara-C (Fig. 7C).
In contrast, these MDR cells remained sensitive to 3-BrPA, which
caused similar inhibitory effect in both parental HL-60 cells and
HL-60/AR cells (MTT assay; Fig. 7D). Using an acute apoptotic
assay (Annexin V/PI staining), we further showed that 50 Amol/L
3-BrPA, which alone caused only <10% apoptotic cells in 24 hours,
was able to substantially increase the cytotoxic effect of doxo-
rubicin, vincristine, or ara-C in HL-60/AR cells (Fig. 7E).
Discussion
The Warburg effect, or increased dependency on glycolysis in
cancer cells, has been a long-standing observation (2, 23). Despite
the consistent findings of this metabolic alteration in a wide
spectrum of human cancers, the therapeutic implications of the
Warburg effect still remain speculative. At the biochemical level,
the Warburg effect is generally attributed to ‘‘respiration injury’’ or
malfunction of the mitochondrial oxidative phosphorylation,
forcing the cells to use the glycolytic pathway to generate ATP.
The major factors contributing to the Warburg effect include
mitochondrial metabolic defects, due in part to mtDNA mutations
and/or aberrant expression of metabolic enzymes, and hypoxic
environment that limits oxygen supply to tumor mass. Unfortu-
nately, the metabolic adaptation in response to these alterations is
associated with reduced sensitivity to common anticancer agents.
Hypoxia is also known to cause resistance to radiation therapy
due in part to induction of hypoxia-inducible factor-1a protein
accumulation (24–27). This imposes a serious challenge in clinical
Figure 5. Induction of ATP depletion and cell death by 3-BrPA in
mitochondrial-deficient cells in comparison with parental cell lines. A, HL-60 cells
and U
 C6F cells were incubated with the indicated concentrations of 3-BrPA for
12 hours, and cellular ATP was determined as described in MATERIALS AND
METHODS. ATP content was 2.6 F 0.1 nmol per 10
6 cells in HL-60 control cells
and 2.2 F 0.1 nmol per 10
6 cells in C6F control cells. B, Raji cells and C8 (U
)
cells were incubated with the indicated concentrations of 3-BrPA for 12 hours.
Cellular ATP was analyzed by HPLC. ATP content was 3.2 F 0.2 nmol per 10
6
cells in Raji control cells and 2.2 F 0.2 nmol per 10
6 cells in C8 control cells.
*, P < 0.05, difference between U
 cells and parental cells. C, comparison of
3-BrPA-induced BAD dephosphorylation (Ser
112) in HL-60 and C6F cells. D,
comparison of 3-BrPA-induced BAD dephosphorylation in Raji and C8 cells. E,
mitochondrial-deficient cells (C6F and C8) were more sensitive to 3-BrPA than
their parental cells (HL-60 and Raji, respectively) and exhibited massive cell
death after the drug incubation (100 Amol/L, 24 hours). Cell death was measured
by flow cytometric analysis after the cells were double stained with Annexin V
and PI. F and G, comparison of time-dependent cell death in U
 cells with the
parental cells. Viable cells were defined as Annexin V/PI double-negative cells.
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and test novel therapeutic strategies to effectively kill cancer cells
and overcome drug resistance associated with hypoxia and
mitochondrial respiratory defects.
In the current study, we hypothesized that the increased
dependency on glycolysis in cancer cells with respiration defects
or under hypoxic conditions could be exploited for therapeutic
benefits and tested this hypothesis in defined experimental systems
using 3-BrPA as a pharmacologic tool to inhibit glycolysis.
Mechanistically, it is logical to speculate that cells with mitochon-
drial defects or in a hypoxic environment are heavily dependent on
glycolysis and are likely more sensitive to glycolytic inhibition.
Indeed, we showed that two separate clones of respiration-deficient
cells derived from human leukemia or lymphoma cells or the
parental cells cultured under hypoxic conditions all exhibited
reduced sensitivity to common anticancer agents, such as doxoru-
bicin, vincristine, ara-C, and taxol (Figs. 1 and 2). In sharp contrast,
these cells showed increased sensitivity to glycolytic inhibition by 3-
BrPA (Figs. 5 and 6). These data provide a proof of principle that it is
possibletouseglycolyticinhibitorstoeffectivelykillcancercellsand
overcome drug resistance associated with the Warburg effect.
It is evident that depletion of cellular ATP is the key event
Figure 6. Cancer cells under hypoxic conditions were more sensitive to
glycolytic inhibition by 3-BrPA. A, inhibition of lactate generation by 3-BrPA in
Raji cells under hypoxic conditions. Raji cells (5  10
5) were resuspended in
1 mL fresh medium and incubated under hypoxia condition for 24 hours in the
presence of the indicated concentrations of 3-BrPA. Lactate levels in the culture
medium were measured as described in MATERIALS AND METHODS.
Columns, mean of three independent experiments; bars, SD. *, lactate levels
below the limit of detection. B, HCT116 cells (1  10
6) were seeded in a culture
plate and incubated for 24 hours. The culture medium was then replaced with
10 mL fresh medium, and the cells were incubated under hypoxic conditions for
36 hours in the presence of the indicated concentrations of 3-BrPA. Lactate
levels in the culture medium were measured as described in MATERIALS AND
METHODS. Columns, mean of three independent experiments; bars, SD. C,
Raji cells under hypoxic conditions were more sensitive to 3-BrPA (100 Amol/L,
24 hours) than under normoxic conditions. Number on the top right corner, %
dead cells. D, HCT116 cells under hypoxic conditions were more sensitive to
3-BrPA (100 Amol/L, 36 hours) than under normoxia condition. Cell death was
measured by flow cytometric analysis after the cells were double stained with
Annexin V and PI.
Figure 7. Comparison of HL-60 and MDR HL-60/AR cells in response to
doxorubicin (A), vincristine (B), ara-C (C), and 3-BrPA (D). Cells were incubated
with the indicated concentrations of each compound, and cell viability was
measured by MTT assay. E, 3-BrPA enhanced the cytotoxic effects of
doxorubicin, ara-C, and vincristine in MDR HL-60/AR cells. Cells were incubated
with the indicated concentrations of each compound in the presence or
absence of a moderately toxic concentration of 3-BrPA (50 Amol/L) for 24 hours.
Cell death was measured by flow cytometric analysis after the cells were
double stained with Annexin V and PI. Columns, average and range of two
independent experiments.
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showed thatthe drug-induced cell death was closely associated with
ATP depletion, which occurred before the appearance of cell death.
An important finding of this study was that inhibition of glycolysis
by 3-BrPA led to the dephosphorylation of BAD, a protein recently
found to integrate glycolysis and apoptosis in the mitochondria
(20). It is known that the antiapoptotic Bcl-2 family members, such
as Bcl-2 and Bcl-XL, are able to bind BAD and BAX and sequester
them in protein complexes to prevent triggering of apoptosis (21).
We now showed that inhibition of glycolysis caused dephosphor-
ylation of BAD, leading to translocation of BAX to the mitochon-
dria, loss of mitochondrial membrane integrity, release of
cytochrome c, and activation of the apoptotic cascades. This is
consistentwith the proapoptotic role of dephosphorylated BAD and
BAX (28–30).
It should be noted that previous studies have suggested that
apoptosis is an ATP-dependent process and that depletion of ATP
tendstocausecelldeathbynecrosis(31–34).Interestingly,celldeath
induced by 3-BrPA seems to contain both apoptotic and necrotic
components (double-positive in Annexin V/PI staining). When the
3-BrPA concentration was relatively low (50 Amol/L) and ATP
depletion was moderate, mainly apoptosis was observed as
evidenced by a large population of cells with positive Annexin V
staining and negative PI staining (Fig. 3C). The amount of ATP that
remained in the cells under these conditions seemed to be sufficient
to support the execution of the apoptotic process. However, at
higher drug concentrations (z100 Amol/L), 3-BrPA caused a severe
ATP depletion and massive necrosis, because the majority of the
cells were positively stained with PI, an indication of loss of
membrane integrity during necrosis (Figs. 3, 5, and 6).
Depletion of cellular ATP by inhibition of glycolysis seems to be
effective in killing cancer cells with a MDR phenotype. It is known
that cells expressing MDR proteins, such as MDR or MRP, require
ATPastheenergysourcetopumpthedrugsubstratesoutofthecells
(35, 36). Thus, it is possible to overcome such drug resistance by
depletion of cellular ATP, causing the pump to fail. The observations
thatcellswithMDRphenotypestillremainedsensitiveto3-BrPAand
that combination of 3-BrPA with doxorubicin, vincristine, or ara-C
enhanced the activity of each drug against the drug-resistant cells
(HL-60/AR) are consistent with this hypothesis. Thus, glycolytic
inhibition may have therapeutic implications in overcoming
multidrug resistance.
The mechanism by which 3-BrPA inhibits glycolysis is mediated
mainly through its inhibition of hexokinase II, the key enzyme
catalyzing the first step of the glycolytic pathway. It is also known
that hexokinase II is highly expressed in malignant cells compared
with normal cells (12, 37), probably reflecting the necessity of high
glycolytic metabolism to maintain sufficient ATP supply in the
tumorcells.Assuch,theuseofglycolyticinhibitors,suchas3-BrPA,
as anticancer agents might provide a preferred therapeutic
selectivity. The ability of 3-BrPA to preferentially kill cancer cells
with mitochondrial defects and tumor cells in a hypoxic
environment provides a biochemical basis to further develop this
class of compounds as novel anticancer agents with potentially
promising therapeutic activity and selectivity. It should be noted,
however, that 3-BrPA is relatively unstable and shows signifi-
cant inhibition of glycolysis only at relatively high concentrations
(100-300 Amol/L) in cell culture. This issue needs to be carefully
considered and addressed in the future development of better
glycolytic inhibitors for the clinical treatment of cancer. Never-
theless, our study suggests that inhibition of glycolysis is an
effective strategy to kill cancer cells and overcome drug resistance
associated with mitochondrial defects and hypoxic conditions.
This novel approach may have broad applications in cancer
treatment, considering the prevalent Warburg effect observed in
a wide spectrum of human cancers.
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